Meropenem Injection PCD Franchise Company in India
BIOFRIL HEALTHCARE is a WHO-GMP certified manufacturer and Meropenem PCD franchise company in India. We supply Meropenem (carbapenem antibiotic) under monopoly district rights with COA-backed batches, tender-ready documentation and dispatch from our Nalagarh (Himachal Pradesh) facility.
Meropenem — Clinical Role
Meropenem is a carbapenem antibiotic used in severe hospital-acquired infections, ventilator-associated pneumonia, complicated intra-abdominal infections, bacterial meningitis, septicaemia and febrile neutropenia. Quality of the lyophilized/finished form, cold-chain discipline where indicated, and batch documentation are what hospitals and drug inspectors check first — and where Biofril’s WHO-GMP process stands out.
Biofril Brands for Meropenem
- FARAMERO-1000 — 1 g lyophilized vial
- FARAMERO-500 — 500 mg vial
- FARAMERO-250 — 250 mg paediatric vial
Why the Meropenem Segment Is Worth Your Franchise
ICU and tertiary-care institutions are standardising on carbapenems for resistant gram-negative sepsis; demand is concentrated in hospital pharmacy and tender supply. With monopoly allocation, you face no internal competition in your district.
What You Get as a Biofril Partner
- Monopoly district rights documented in the agreement
- COA with every batch + WHO-GMP plant documentation for hospital and government tenders
- Promotional kit — visual aids, MR kits, doctor samples, scientific literature, net rate lists
- Manageable MOQ and one-business-day commercial response
- Full critical-care basket — combine Meropenem with our complete injectable range under one agreement: Critical Care PCD Franchise
How to Start
- Share your district and current network via the enquiry form, +91 97658 93730 or WhatsApp.
- Receive net rates, product dossier and territory confirmation within one business day.
- Execute the monopoly agreement, place the inaugural order, receive stock + promo kit.
Who Buys Meropenem in Your District
Meropenem is a hospital-only product. Before you place your first order, map the buyers below and estimate how many of them you can reach every week.
- ICUs and HDUs — the largest users, mainly for sepsis, ventilator-associated pneumonia and hospital-acquired infections. ICU bed count is the best single predictor of meropenem demand in a district.
- NICUs and paediatric wards — the reason hospitals ask for a 250 mg paediatric vial (FARAMERO-250) alongside the 500 mg and 1 g strengths.
- Oncology and haematology units — febrile neutropenia protocols in cancer centres and day-care chemotherapy units.
- General and gastro-surgery — complicated intra-abdominal infections and post-operative sepsis.
- Hospital pharmacies and institutional buyers — purchase decisions often sit with the pharmacy committee, not only the prescribing doctor.
Antibiotic Stewardship: What It Means for Your Sales
Meropenem is classified in the WHO AWaRe Watch group, and many Indian hospitals run antimicrobial stewardship programmes that restrict carbapenems to culture-guided or specialist-approved use. For a PCD partner this has two consequences:
- Volume comes from formulary entry, not from promoting to individual doctors. Keep the WHO-GMP certificate, product permission and batch-wise Certificate of Analysis ready for the pharmacy and therapeutics committee.
- Demand is steady rather than seasonal, because restricted use still means daily use in every ICU that admits septic patients.
Stocking and Compliance Checklist
- Meropenem is a prescription-only medicine; carbapenems fall under Schedule H1, which requires a separate sale register — follow the marking on each label and your State Drugs Control rules.
- Store the dry powder vials as printed on the label, away from heat and moisture; reconstitution is done by hospital staff at the point of use.
- Stock all three strengths in proportion to your buyer mix — 1 g for adult ICUs, 500 mg for step-down and smaller hospitals, 250 mg for paediatrics.
- Track batch numbers and expiry on every invoice so a hospital can trace any vial back to its COA.
Build a Hospital Basket Around Meropenem
An ICU that buys meropenem also buys vancomycin for Gram-positive cover, amikacin, IV pantoprazole for stress-ulcer prophylaxis and enoxaparin for DVT prophylaxis. Offering the full basket from one WHO-GMP manufacturer simplifies the hospital’s vendor list and raises your order value. See the 10-injectable starter portfolio and the full critical care PCD range.
FAQs — Meropenem PCD Franchise
Do I need a drug licence?
Yes — Form 20B/21B wholesale licence and GST registration. We guide first-time applicants.
Is Meropenem supplied with tender documentation?
Yes — WHO-GMP certificates, COAs and product dossiers are prepared in advance for institutional and GeM tenders.
Can I take only Meropenem or the full injectable range?
Both are possible; most partners take the complete critical-care basket for better prescriber coverage and freight economics.
Which territories are open?
District-level monopoly availability is confirmed within one business day of your enquiry.
Which hospital departments buy meropenem most?
ICUs and HDUs, followed by NICUs, oncology/haematology units and surgical wards. Hospitals with ventilated beds are the core buyers.
Why do hospitals want 250 mg, 500 mg and 1 g meropenem?
Dosing differs between neonates, children and adults, and smaller vials reduce wastage. Offering FARAMERO-250, FARAMERO-500 and FARAMERO-1000 lets one supplier cover every ward.
Does antibiotic stewardship reduce meropenem demand?
It restricts unnecessary use, but carbapenems remain essential for resistant and severe infections. Demand shifts to hospitals with formal formularies, which is why documentation and consistent quality matter more than price.
Apply Now — Meropenem Injection PCD Franchise & Supplier India
Share your details — our franchise team will call you back with the product list, franchise rates and monopoly-area availability for your district.